Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 6/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.36 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.36 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.34 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.32 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
| ▸ | RARG | P13631 | 2/20 | 0.32 |
| ▸ | RORC | P51449 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1762495 | 0.84 | L3MBTL1 (0.40) | TRPA1TRPV1MALT1SLC16A3SLC16A1 | |
| SCHEMBL29757297 | 0.84 | L3MBTL1 (0.40) | TRPA1TRPV1MALT1SLC16A3SLC16A1 | |
| SCHEMBL29185098 | 0.83 | TRPA1 (0.35) | TRPA1TRPV1MALT1SLC16A3SLC16A1 | |
| SCHEMBL24949712 | 0.83 | TRPA1 (0.36) | TRPA1TRPV1MALT1SLC16A3SLC16A1 | |
| SCHEMBL951828 | 0.81 | MALT1 (0.36) | TRPA1TRPV1MALT1SLC16A3SLC16A1 | |
| SCHEMBL27962696 | 0.81 | ALDH1A1 (0.40) | TRPA1TRPV1MALT1SLC16A3SLC16A1 | |
| SCHEMBL16014505 | 0.81 | NPC1 (0.40) | TRPA1SLC16A3SLC16A1NTRK1HIF1A | |
| SCHEMBL27925516 | 0.80 | GCK (0.35) | TRPA1TRPV1MALT1HIF1A | |
| SCHEMBL2586280 | 0.80 | MALT1 (0.40) | TRPA1MALT1SLC16A3SLC16A1DHODH | |
| SCHEMBL16014767 | 0.80 | TRPA1 (0.36) | TRPA1TRPV1MALT1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8697734-B2 | Method for controlling particular insect pests by applying anthranilamide compounds | E I DU PONT DE NEMOURS AND COMPANY (US) | 2014-04-15 | — | — | US | disclosed |
| US-20130028879-A1 | METHOD FOR CONTROLLING PARTICULAR INSECT PESTS BY APPLYING ANTHRANILAMIDE COMPOUNDS | E I DU PONT DE NEMOURS AND COMPANY (US) | 2013-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130028879-A1 | METHOD FOR CONTROLLING PARTICULAR INSECT PESTS BY APPLYING ANTHRANILAMIDE COMPOUNDS | ANTXR2, CYP4X1, PRDX1 | TRPA1 409/4885TRPV1 1476/4885MALT1 2245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.